Logo Image
|Webcasts|February 27, 2020

The Current and Future Impact of Artificial Intelligence (AI) on Pharmacovigilance

In this webcast, Safety Experts – Dr. Mirza Rahman from Otsuka and Bruce Palsulich from Oracle Health Sciences - will discuss the current, near, and longer-term opportunities for Artificial Intelligence in Pharmacovigilance. Live: Thursday, Feb. 27, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET On demand available after airing until Feb. 27 2021. Register free

Register free: http://www.appliedclinicaltrialsonline.com/act_w/future_impact

Event Overview: 

Artificial Intelligence (AI) and Machine Learning are rapidly seeing adoption in all aspects of our daily lives. These advanced technologies have the potential to significantly impact the way that Pharmacovigilance is performed from individual adverse event processing through data analytics and signal detection to predictive analysis. In this webcast our presenters from Oracle Health Sciences and Otsuka Pharmaceutical will discuss:

  • Current, near, and longer term opportunities for AI in PV

  • Advances in AI in medicine and medical perspective on AI in PV

  • Identifying and overcoming barriers for adoption: technical, operational, social, scientific, privacy, etc.

  • Strategies for successful AI implementation projects

Key Learning Objectives:

  • Best Practices in Safety Case Management

  • Insure cost control, quality, efficiency and compliance

  • Understand the true power of AI, Predictive Analytics and Data mining

Speakers: Bruce Palsulich, Vice President Safety Product Strategy, Oracle Health Sciences

Mirza Rahman, MD, MPH, Senior Vice President & Global Head of Pharmacovigilance, Otsuka Pharmaceutical Development & Commercialization, Inc.

Time and date: Thursday, Feb. 27, 2020 at 11am EST | 8am PST | 4pm GMT | 5pm CET

On demand available after airing until Feb. 27, 2021.

Sponsor: Oracle Health Sciences

Register free: http://www.appliedclinicaltrialsonline.com/act_w/future_impact

Related to this article

View more
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
The Human Side of Clinical Trials: How Measuring Readiness at Training Predicts Trial Risk Before It Shows Up in the Data
This episode of The Human Side of Clinical Trials, hosted by Brian S. McGowan, PhD, FACEHP, chief learning officer and co-founder of ArcheMedX, Inc., and Kelly Ritch, chief operating officer of ArcheMedX, Inc., explores why training completion metrics like attendance and quiz scores fail to capture true study readiness, and how measuring both competence and confidence can reveal trial risks before enrollment even begins.
Read more
What the Epilepsy Community Has Taught Us About Trial Feasibility
What the Epilepsy Community Has Taught Us About Trial Feasibility
In this video interview, Amélie Lothe, global medical community head for rare epilepsies at UCB Pharma, shares what she has learned firsthand from families living with Dravet syndrome and CDKL5 deficiency disorder about what makes trial participation possible—and what makes it not.
Read more